You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 10, 2025

CLINICAL TRIALS PROFILE FOR METHOCARBAMOL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Methocarbamol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02432456 ↗ Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients Completed Medical College of Wisconsin Phase 4 2015-09-01 This study will evaluate the effectiveness of ketamine infusions in the management of acute pain resulting from broken ribs suffered following a blunt trauma. Half of patients will receive the institutional standard of care and a placebo infusion (no active medication). The other half of patients will receive the institutional standard of care and a ketamine infusion. All subjects and staff will be blinded as to whether they are receiving placebo or ketamine.
NCT02642874 ↗ Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients Unknown status Tanta University Phase 3 2017-04-01 Muscle cramps markedly affect the quality of life in cirrhotic patients with no highly effective drug. Methocarbamol is a central muscle relaxant used to treat skeletal muscle spasms. The mechanism of action of methocarbamol is currently unknown, but may involve the inhibition of carbonic anhydrase. Methocarbamol has a high therapeutic index, i.e. a wide range of safe and effective dosages.
NCT02665286 ↗ Orphenadrine and Methocarbamol for LBP Completed Montefiore Medical Center Phase 4 2016-03-01 Low back pain is a common cause of visit to emergency department. It is not clear if skeletal muscle relaxants are of benefit for patients with acute low back pain. This is a randomized study to determine if skeletal muscle relaxants, when combined with naproxen, improve outcomes more than naproxen alone
NCT02831569 ↗ Japanese IP-TN Trial Completed SSP Co., Ltd. Phase 3 2016-07-27 This is an open-label, single-group, multi-centre trial to confirm the safety and efficacy of loxoprofen sodium/methocarbamol ( IP-TN) when administered orally for 2 weeks to patients with low back pain, scapulohumeral periarthritis, or cervico-omo-brachial syndrome associated with muscle strain. More than 90 patients will be screened to enroll approximately 80 patients in the trial. After giving written informed consent, patients will be enrolled in the trial. Patients who are considered eligible for the trial by the Investigator after consent and complete the trial procedures and assessments at Visit 1 will receive the trial medication and enter the open-label treatment period of 2 weeks. Patients who complete the open-label treatment period will enter the follow-up period of 1 week and complete the trial after confirmation at the last visit (or phone interview).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Methocarbamol

Condition Name

Condition Name for Methocarbamol
Intervention Trials
Low Back Pain 2
Nephrolithiasis 1
Addiction Opiate 1
Pain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Methocarbamol
Intervention Trials
Fractures, Bone 2
Back Pain 2
Low Back Pain 2
Hernia, Ventral 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Methocarbamol

Trials by Country

Trials by Country for Methocarbamol
Location Trials
United States 6
Italy 2
Japan 1
Egypt 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Methocarbamol
Location Trials
Texas 1
Illinois 1
Minnesota 1
West Virginia 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Methocarbamol

Clinical Trial Phase

Clinical Trial Phase for Methocarbamol
Clinical Trial Phase Trials
Phase 4 6
Phase 3 3
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Methocarbamol
Clinical Trial Phase Trials
Completed 3
Not yet recruiting 3
Recruiting 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Methocarbamol

Sponsor Name

Sponsor Name for Methocarbamol
Sponsor Trials
Hippocrates Research 1
Aziende Chimiche Riunite Angelini Francesco S.p.A 1
Medical College of Wisconsin 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Methocarbamol
Sponsor Trials
Other 11
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Methocarbamol: Clinical Trials, Market Analysis, and Projections

Introduction

Methocarbamol is a skeletal muscle relaxant commonly used to alleviate discomfort associated with acute, painful musculoskeletal conditions. This article delves into the recent clinical trials, market analysis, and future projections for methocarbamol, providing a comprehensive overview of its efficacy, market trends, and potential growth.

Clinical Trials and Efficacy

Acute Low Back Pain (ALBP)

Recent clinical trials have evaluated the efficacy of methocarbamol in treating acute low back pain. A systematic review published in 2024 analyzed three studies involving 405 ALBP patients, with 163 receiving methocarbamol. The results indicated that methocarbamol showed potential for improving pain outcomes at one week when combined with NSAIDs like Indomethacin or Naproxen. However, it was less effective than diazepam in the short-term management of pain, particularly at 30 and 60 minutes post-administration[1].

Another study conducted in Iran compared the efficacy of intravenous methocarbamol and diazepam in patients with acute low back pain. While both drugs reduced pain scores after 60 minutes, diazepam was slightly more effective but associated with a higher risk of drowsiness[4].

Mechanism of Action

Methocarbamol's mechanism of action is not fully understood but is believed to involve central nervous system depressant activity. It blocks spinal polysynaptic reflexes, decreases nerve transmission in spinal and supraspinal pathways, and prolongs the refractory period of muscle cells. This action does not affect muscle fiber contraction, motor end plates, or nerve fibers[5].

Market Analysis

Global Muscle Relaxant Market

The global muscle relaxant market is expected to grow significantly due to the increasing prevalence of musculoskeletal conditions and lower back pain. By 2037, the market is projected to reach USD 8.06 million, growing at a CAGR of 6.9% from 2025 to 2037. The neuromuscular blockers segment is anticipated to garner the largest revenue, driven by the growing number of patients with neuromuscular disorders[2].

Methocarbamol Tablets Market

The methocarbamol tablets market was valued at USD 1.2 billion in 2023 and is expected to reach USD 1.9 billion by 2031, growing at a CAGR of 5.8% from 2024 to 2031. This growth is driven by the rising incidence of musculoskeletal injuries and disorders, particularly among the elderly and active populations. The market expansion is also supported by the increasing availability of generic methocarbamol tablets and advancements in pharmaceutical production[3].

Market Segments and Trends

Application Segments

Methocarbamol tablets are categorized based on their applications, including muscle relaxation, pain relief, spasm treatment, back pain, and musculoskeletal disorders. The demand for methocarbamol is boosted by its efficacy in treating these conditions, especially in the context of rising sports-related injuries and an aging population[3].

Product Segments

The market is segmented by product type, including oral tablets, extended-release tablets, generic methocarbamol, combination tablets, and powder formulations. The availability of various formulations enhances treatment accessibility and contributes to market growth[3].

Geographical Segments

The methocarbamol market is analyzed across geographical regions such as North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. Each region's market size and growth prospects are influenced by local healthcare policies, population demographics, and the prevalence of musculoskeletal conditions[3].

Growth Drivers and Challenges

Growth Drivers

  • Increasing Prevalence of Musculoskeletal Conditions: The global rise in musculoskeletal disorders, including lower back pain, muscle spasms, and other related conditions, drives the demand for methocarbamol.
  • Aging Population: The aging population is more vulnerable to musculoskeletal issues, contributing to the growing need for muscle relaxants like methocarbamol.
  • Advancements in Pharmaceutical Production: Improvements in pharmaceutical production, including the development of generic formulations, enhance treatment accessibility and affordability[2][3].

Challenges

  • Limited Clinical Evidence: Despite its widespread use, there is a need for more rigorous prospective controlled studies to fully understand the efficacy and long-term effects of methocarbamol, especially when combined with other medications[1].
  • Adverse Effects: Common adverse effects such as nausea and drowsiness, particularly when compared to other muscle relaxants like diazepam, can impact patient compliance and satisfaction[1][4].

Future Projections

Market Expansion

The methocarbamol market is expected to continue growing due to the increasing demand for effective muscle relaxants. The focus on research and development to improve therapeutic efficacy and reduce adverse effects will further accelerate market expansion[3].

Clinical Research

Future clinical trials should address the limitations of current studies by including larger sample sizes and control groups to better understand the specific implications of methocarbamol in various treatment scenarios. This will lead to a more comprehensive approach to its use in clinical settings[1].

Key Takeaways

  • Efficacy in ALBP: Methocarbamol shows potential in improving pain outcomes for acute low back pain patients, especially when combined with NSAIDs.
  • Market Growth: The global methocarbamol market is projected to grow significantly, driven by the increasing prevalence of musculoskeletal conditions and advancements in pharmaceutical production.
  • Growth Drivers: The aging population, rising sports-related injuries, and improvements in generic formulations are key drivers of market growth.
  • Challenges: There is a need for more rigorous clinical trials to fully understand the efficacy and long-term effects of methocarbamol.

FAQs

What is the primary use of methocarbamol?

Methocarbamol is primarily used as a skeletal muscle relaxant to alleviate discomfort associated with acute, painful musculoskeletal conditions.

How effective is methocarbamol in treating acute low back pain?

Methocarbamol shows potential in improving pain outcomes for acute low back pain patients, especially when combined with NSAIDs, although it may be less effective than diazepam in the short term.

What are the common adverse effects of methocarbamol?

Common adverse effects include nausea and drowsiness, with the latter being more pronounced when compared to other muscle relaxants like diazepam.

What drives the growth of the methocarbamol market?

The growth is driven by the increasing prevalence of musculoskeletal conditions, an aging population, and advancements in pharmaceutical production, including the availability of generic formulations.

What are the future projections for the methocarbamol market?

The market is expected to continue growing, with a projected value of USD 1.9 billion by 2031, driven by increasing demand and ongoing research to improve therapeutic efficacy.

Sources

  1. Bahria Wided, Makhlouf Yasmine: "Effect of Methocarbamol on acute low back pain: A systematic review." F1000Research, 2024.
  2. ResearchNester: "Muscle Relaxant Drugs Market Size & Share, Growth Forecasts 2037." ResearchNester, 2024.
  3. MarketResearchIntellect: "Methocarbamol Tablets Market Size, Trends and Forecast." MarketResearchIntellect, 2024.
  4. PubMed: "Methocarbamol versus diazepam in acute low back pain." PubMed, 2023.
  5. DrugBank: "Methocarbamol: Uses, Interactions, Mechanism of Action." DrugBank.

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.